Page 146 - NobleCon20-Book-Project

Health Care
Date November 18, 2024 Health Care
52wk High $42.92
52wk Low $1.88 SeaStar Medical Holding Co ICU $1.95
3513 Brighton Boulevard
Denver, CO 80216

(USD - in millions) www.seastarmedical.com
Market Cap 9.6
Enterprise 7.5
Basic Shares Out. 4.36 COMPANY OVERVIEW
Float 4.29
Institutional Holdings 10.23% Detailed Analysis:Channelchek.com
Short Interest 0.29
Avg. 90-Day Volume 0.12 SeaStar Medical is a commercial-stage medical technology company
that is redefining how extracorporeal therapies may reduce the
consequences of excessive inflammation on vital organs. SeaStar
Medical’s novel technologies rely on science and innovation to provide
EPS Data life-saving solutions to critically ill patients. The Company is developing
and commercializing cell-directed extracorporeal therapies that target
2022 2023 2024 the effector cells that drive systemic inflammation, causing direct tissue
CQ1 N/A (10.00) (4.75) damage and secreting a range of pro-inflammatory cytokines that
CQ2 N/A (6.25) (1.03) initiate and propagate imbalanced immune responses.

CQ3 N/A (9.25) (1.10)
CQ4 N/A (4.75) (1.10)
CY (70.00) (30.25) (7.99) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) -0.49
ROE (ttm) NM
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
3513 Brighton Denver CO 80216

Key Executives
CEO: Schlorff, Eric
CFO: Green, David
COO: Mullen, Tom
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert LeBoyer MEMBERS: FINRA, SIPC, MSRB
Following the conference, complete video library of presentations will be
rleboyer@noblelsp.com available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures